Valhalla, NYNCT04099966Now EnrollingIRB Ready

Acute Leukemia Clinical Trial in Valhalla, NY

Access cutting-edge acute leukemia treatment through this phase 2 clinical trial at a research site in Valhalla. Study-provided care at no cost to qualified participants.

Sponsored by Mitchell Cairo

Quick Self-Assessment

See if you qualify for this Valhalla location

Preparing your pre-screening questions…

Expert Care in Valhalla

Access acute leukemia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related acute leukemia treatment provided free

Apply for This Valhalla Location

Check if you qualify for this acute leukemia clinical trial in Valhalla, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Valhalla

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Valhalla site if eligible
  4. 4Begin participation

About This Acute Leukemia Study in Valhalla

Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion. All other treatment is standard of care.

Sponsor: Mitchell Cairo

Who Can Participate

Inclusion Criteria

ALL:ALL high risk including one or more of the following: (t(9;22) or 11q23 chromosomal abnormality, primary induction failure (\<15% blasts at time of registration), mixed phenotype acute leukemia (MPAL), persistent MRD (\<0.01% by flow or persistent abnormal karyotype detected by cytogenetics) or hypodiploidy (44 chromosomes)) in first remission ' ALL in second remission and beyond;
AML: History of AML induction/reinduction Failure (\<15% blasts at time of registration); AML in CR1 with poor cytogenetics (i.e. 12p, 5a, -7, FLT3 mutation/duplication, t(9;11) and others); AML with persistent minimal residual disease (MRD) in CR1(\<0.01% on flow or persistent abnormal karyotype detected by cytogenetics); AML CR2 or beyond; AML in refractory relapse but ≤15% bone marrow leukemia blasts; Therapy-related AML
High Risk Myelodysplastic syndrome (MDS) 4 Lymphoma: Hodgkin (HL) or Non-Hodgkin (NHL): HL or NHL in induction failure; HL or NHL in PR1 or PR2 ; HL or NHL in CR2 or subsequent remission 5\. Bone marrow failure syndromes: Kostmann syndrome refractory or intolerant to granulocyte colony-33stimulating factor; Diamond-Blackfan anemia refractory or intolerant to corticosteroids and/or cyclosporine'; amegakaryocytic thrombocytopenia 6. Sickle Cell Disease (Homozygous Hemoglobin S Disease, or Hemoglobin S β 0/+ thalassemia, or Hemoglobin SC Disease) 7. age 0-30 years 8. adequate organ function

Exclusion Criteria

Females who are pregnant or breast-feeding are not eligible.
Patients with documented uncontrolled infection at the time of study entry are not eligible.
Karnofsky/Lansky (age appropriate) Performance Score \<60
Demonstrated lack of compliance with medical care
Patients who have received allogeneic HSCT within 6 months, unless being done as a boost.
Patients with active \<Grade 2 GVHD.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Valhalla?

Yes, this clinical trial (NCT04099966) has an active research site in Valhalla, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Acute Leukemia Treatment Options in Valhalla, NY

If you're searching for acute leukemia treatment options in Valhalla, NY, this clinical trial (NCT04099966) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Valhalla research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced acute leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all acute leukemia clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in Valhalla, NY

See all leukemia clinical trials recruiting in Valhalla — not just this study.

Browse Leukemia Trials in Valhalla →

Browse More Trials by Condition

Leukemia TrialsHeart Attack TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Valhalla?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Valhalla, NY